Ketamine Therapy Market Analysis, Size, Share & Growth Forecast 2026–2034

Esketamine Spravato REMS 2-Hour Supervised Administration in Certified Healthcare Setting Preventing the Dissociation and Blood Pressure Monitoring Gap Has Created the In-Office Treatment Model That Contrasts With the IV Ketamine Off-Label Clinic and At-Home Telehealth Prescribing Practices.Johnson and Johnson's Spravato received FDA approval for treatment-resistant depression in 2019 and an expanded indication for depressive symptoms in adults with MDD with suicidal ideation in 2020, generating commercial revenues that have exceeded projections as psychiatrists establish REMS-certified Spravato treatment facilities in outpatient settings. The 2024 monotherapy approval based on EMERALD-1 and EMERALD-2 data demonstrating Spravato plus clinical standard of care superiority over placebo in MDD without prior antidepressant inadequate response expanded the eligible population beyond TRD to the much larger MDD population initiating treatment. The suicide risk reduction approval creates a distinct acute use case where Spravato is administered over days to weeks to bridge the 2-6 week delay before conventional antidepressants achieve therapeutic effect in patients at imminent suicide risk.

IV Ketamine Off-Label Clinic Proliferation to 600 to 800 US Locations Delivering 0.5 mg/kg Subanesthetic Infusion Without FDA Depression Indication or REMS Programme Has Created the Regulatory Grey Area That the Schedule III Anaesthetic Licence Enables for the Compounded Formulation.Intravenous racemic ketamine 0.5 mg/kg infused over 40 minutes has been administered in ketamine infusion clinics for TRD, bipolar depression, PTSD, and chronic pain management, with retrospective series showing response rates of 50-70% in TRD patients who have failed 4 or more prior antidepressant trials. The absence of an approved racemic ketamine product for psychiatric indications creates a compounding pharmacy-dependent market where pricing varies from USD 500 to USD 1,500 per infusion and insurance coverage is rarely available, creating access inequities that favour patients with financial resources or access to academic medical centres with insurance contracts covering infusion protocols. The legal and regulatory complexity of prescribing a Schedule III controlled substance for off-label psychiatric indications in settings not equipped for general anaesthesia has driven professional society guidelines from ASRA and ASCRS that establish minimum safety standards for outpatient ketamine infusion administration.

At-Home Compounded Ketamine Troche and Oral Capsule Telehealth Prescribing Without In-Person Monitoring Has Prompted FDA Enforcement Letters Addressing the Safety Monitoring Gap for the Schedule III Controlled Substance Dissociation Side Effect That Unsupervised Administration Creates.Ketamine's ketamine R-enantiomer produces the dissociative psychotomimetic effects that require REMS-monitored in-clinic administration, and several companies including Clexio Biosciences and Naurex are developing ketamine analogues that preserve the NMDA antagonism-mediated antidepressant mechanism while reducing dissociation and abuse potential. Rapastinel, a partial NMDA glycine-site agonist from Allergan that failed Phase 3 for MDD, and REL-1017 low-trap NMDA antagonist from Relmada Therapeutics in Phase 3 represent the broader class of glutamatergic modulators that seek to capture ketamine's rapid antidepressant mechanism without the ketamine class's dissociative and controlled-substance complexities. The regulatory pathway for non-dissociative ketamine analogues would not require the REMS programme that burdens Spravato prescribing, potentially enabling outpatient and even primary-care administration that could expand rapid-acting antidepressant access dramatically beyond the current ketamine infusion clinic infrastructure.

For related market intelligence, see the Depression Drug Market.